Michael D. Devous
YOU?
Author Swipe
View article: Concordance between visual interpretation and quantitative analysis of [18F]flortaucipir pet images
Concordance between visual interpretation and quantitative analysis of [18F]flortaucipir pet images Open
Background Positron emission tomography (PET) imaging with [18F]flortaucipir allows for in‐vivo visualization of aggregated tau in Alzheimer’s disease (AD). The FDA‐approved label for [18F]flortaucipir PET provides a standardized, clinical…
View article: CONCORDANCE BETWEEN VISUAL INTERPRETATION AND QUANTITATIVE ANALYSIS OF [<sup>18</sup>F]FLORTAUCIPIR PET IMAGES
CONCORDANCE BETWEEN VISUAL INTERPRETATION AND QUANTITATIVE ANALYSIS OF [<sup>18</sup>F]FLORTAUCIPIR PET IMAGES Open
Background Positron emission tomography (PET) imaging with [ 18 F]flortaucipir allows for in‐vivo visualization of aggregated tau in Alzheimer’s disease (AD). The FDA‐approved label for [ 18 F]flortaucipir PET provides a standardized, clin…
View article: A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles
A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles Open
Alzheimer’s disease is defined by the presence of β-amyloid plaques and neurofibrillary tau tangles potentially preceding clinical symptoms by many years. Previously only detectable post-mortem, these pathological hallmarks are now identif…
View article: Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity
Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity Open
Importance An increased tau positron emission tomography (PET) signal in the medial temporal lobe (MTL) has been observed in older individuals in the absence of amyloid-β (Aβ) pathology. Little is known about the longitudinal course of thi…
View article: Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression
Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression Open
View article: Prevalence and longitudinal clinical outcomes of negative, moderate, and advanced [<sup>18</sup>F]flortaucipir PET visual patterns across the Alzheimer's disease spectrum
Prevalence and longitudinal clinical outcomes of negative, moderate, and advanced [<sup>18</sup>F]flortaucipir PET visual patterns across the Alzheimer's disease spectrum Open
Background The advent of positron emission tomography (PET) imaging with tracers such as [ 18 F]flortaucipir (FTP) has allowed in‐vivo visualization of aggregated tau in Alzheimer’s disease (AD). Recently, a clinically applicable visual in…
View article: Tau PET as a prognostic marker in preclinical and prodromal Alzheimer’s disease
Tau PET as a prognostic marker in preclinical and prodromal Alzheimer’s disease Open
Background Tau PET tracers have proven useful for diagnostic purposes, but their prognostic utility for predicting future cognitive changes over time is unclear. We aimed to examine the prognostic accuracy of [ 18 F]flortaucipir and [ 18 F…
View article: A Local Accumulation Connected Spread Model of Neurofibrillary Tangle Propagation in the Human Neocortex
A Local Accumulation Connected Spread Model of Neurofibrillary Tangle Propagation in the Human Neocortex Open
The objective of this work was to develop a biophysical model that would elucidate the role of the brain neurofibrillary tangles (NFTs) play in the development of Alzheimer's disease (AD). AD is a devastating neurodegenerative disease, and…
View article: Cerebral blood volume in Alzheimer's disease and correlation with tissue structural integrity
Cerebral blood volume in Alzheimer's disease and correlation with tissue structural integrity Open
A vascular component is increasingly recognized as important in Alzheimer's disease (AD). We measured cerebral blood volume (CBV) in patients with probable AD or Mild Cognitive Impairment (MCI) and in elderly non-demented subjects using a …
View article: Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease Open
The findings of this prognostic study suggest that tau PET is a promising tool for predicting cognitive change that is superior to amyloid PET and MRI and may support the prognostic process in preclinical and prodromal stages of AD.
View article: Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Four distinct trajectories of tau deposition identified in Alzheimer’s disease Open
View article: Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease Open
ClinicalTrials.gov Identifier: NCT02016560 and NCT03901105.
View article: Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease Open
Introduction Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease (AD)‐modifying treatment. As previously reported, amyloid beta (Aβ) neuritic plaque b…
View article: Neuropathological diagnoses of subjects autopsied in the phase 3 clinicopathological study of flortaucipir F18 PET imaging
Neuropathological diagnoses of subjects autopsied in the phase 3 clinicopathological study of flortaucipir F18 PET imaging Open
Background Avid Radiopharmaceuticals conducted a prospective case‐control clinicopathological study of flortaucipir F18 PET Imaging (AV‐1451‐A16) from October 2015 through June 2018. This presentation is an initial report of the detailed n…
View article: The accumulation rate of tau aggregates is higher in females and younger individuals
The accumulation rate of tau aggregates is higher in females and younger individuals Open
Background Tau pathology is a key hallmark of Alzheimer’s disease (AD), but factors modifying the rate of tau accumulation are still largely unknown. Tau‐PET allows tau pathology to be visualized in vivo in AD. Our aim was to study factors…
View article: The impact of demographic, clinical, genetic, and imaging variables on tau PET status
The impact of demographic, clinical, genetic, and imaging variables on tau PET status Open
View article: The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects Open
The development of tau-PET allows paired helical filament tau pathology to be visualized in vivo. Increased knowledge about conditions affecting the rate of tau accumulation could guide the development of therapies halting the progression …
View article: Characterizing the spatiotemporal variability of Alzheimer’s disease pathology
Characterizing the spatiotemporal variability of Alzheimer’s disease pathology Open
Alzheimer’s disease (AD) is characterized by the progressive spread of tau pathology throughout the cerebral cortex. The pattern of spread is thought to be fairly consistent across individuals, though more recent work has demonstrated subs…
View article: Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study Open
View article: Positron Emission Tomography Imaging With [<sup>18</sup>F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
Positron Emission Tomography Imaging With [<sup>18</sup>F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes Open
Importance Positron emission tomography (PET) may increase the diagnostic accuracy and confirm the underlying neuropathologic changes of Alzheimer disease (AD). Objective To determine the accuracy of antemortem [ 18 F]flortaucipir PET imag…
View article: Additional file 1 of Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
Additional file 1 of Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study Open
Additional file 1: Supplemental Figure 1. Example of PET ROI hand drawn to match pathology sample block, in this case right amygdala. Note the PET image is in radiologic orientation so the relevant ROI for this example is on the left of th…
View article: P3‐322: RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM
P3‐322: RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM Open
Neurofibrillary tangles represent a pathological hallmark of Alzheimer's disease (AD) that has been associated with neurodegeneration. We sought to explore regional relationships between tau (flortaucipir) and neurodegeneration in a clinic…
View article: DT‐01‐05: TEMPORAL LOBE QUANTITATION OF FLORTAUCIPIR PET IMAGES MAY IMPROVE DETECTION OF INTERMEDIATE NEUROFIBRILLARY TANGLE PATHOLOGY IN AUTOPSY‐VALIDATED CASES
DT‐01‐05: TEMPORAL LOBE QUANTITATION OF FLORTAUCIPIR PET IMAGES MAY IMPROVE DETECTION OF INTERMEDIATE NEUROFIBRILLARY TANGLE PATHOLOGY IN AUTOPSY‐VALIDATED CASES Open
We previously presented [Mintun, HAI 2019] a flortaucipir PET image interpretation methodology with statistical power for predicting autopsy-confirmed neurofibrillary tangle (NFT) scores of B3 (Braak V or VI). Recently, we developed [Kotar…
View article: IC‐P‐162: RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM
IC‐P‐162: RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM Open
Neurofibrillary tangles represent a pathological hallmark of Alzheimer's disease (AD) that has been associated with neurodegeneration. We sought to explore regional relationships between tau (flortaucipir) and neurodegeneration in a clinic…
View article: O3‐02‐03: ASSOCIATION BETWEEN APOE ISOFORM AND 18‐MONTH TAU ACCUMULATION
O3‐02‐03: ASSOCIATION BETWEEN APOE ISOFORM AND 18‐MONTH TAU ACCUMULATION Open
The ε4 isoform of the apolipoprotein gene (APOE) has been established as a risk-factor for development of both early and late-onset Alzheimer's Dementia (AD). Substantial evidence suggests ε4 carriers accumulate amyloid and demonstrate cog…
View article: P3‐026: IMPLEMENTATION OF DUAL‐PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE‐AD CLINICAL TRIAL
P3‐026: IMPLEMENTATION OF DUAL‐PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE‐AD CLINICAL TRIAL Open
Dual-phase florbetapir PET holds promise as a dual-biomarker imaging approach, measuring both amyloid pathology (delayed phase started 50 minutes after tracer administration) and regional cerebral perfusion (early phase started at the time…
View article: A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer’s Disease
A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer’s Disease Open
Alzheimer’s disease (AD) is the most common cause of neurodegenerative cognitive impairment, defined by abnormal accumulations of amyloid-β and tau. Approaches directly targeting these proteins have not resulted in a disease modifying ther…
View article: Tau Positron-Emission Tomography in Former National Football League Players
Tau Positron-Emission Tomography in Former National Football League Players Open
A group of living former NFL players with cognitive and neuropsychiatric symptoms had higher tau levels measured by PET than controls in brain regions that are affected by CTE and did not have elevated amyloid-beta levels. Further studies …
View article: A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia Open
The advent of tau-targeted PET tracers such as flortaucipir (18F) (flortaucipir, also known as 18F-AV-1451 or 18F-T807) have made it possible to investigate the sequence of development of tau in relationship to age, amyloid-β, and to the d…
View article: Parametric methods for [<sup>18</sup>F]flortaucipir PET
Parametric methods for [<sup>18</sup>F]flortaucipir PET Open
[ 18 F]Flortaucipir is a PET tau tracer used to visualize tau binding in Alzheimer’s disease (AD) in vivo. The present study evaluated the performance of several methods to obtain parametric images of [ 18 F]flortaucipir. One hundred and t…